Capital International Sarl Acquires 41,398 Shares of Align Technology, Inc. $ALGN

Key Points

• Capital International Sarl boosted its stake in Align Technology by 107.6% in Q3, buying 41,398 shares to hold 79,861 shares valued at about $10 million (≈0.11% of the company).
• Align beat the latest quarter's estimates with EPS $3.29 vs. $2.99 expected and revenue of $1.05 billion vs. $1.03 billion, showing year‑over‑year growth in both revenue and earnings.
• Several brokerages raised price targets (examples: Stifel to $210, Evercore to $200, UBS to $185), but the stock's consensus remains a "Hold" with a mean target of $198.08 (six Buys, eight Holds).

Capital International Sarl increased its holdings in Align Technology, Inc. (NASDAQ:ALGN - Free Report) by 107.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,861 shares of the medical equipment provider's stock after buying an additional 41,398 shares during the period. Capital International Sarl owned 0.11% of Align Technology worth $10,000,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in ALGN. Rothschild Investment LLC grew its position in Align Technology by 140.3% during the second quarter. Rothschild Investment LLC now owns 149 shares of the medical equipment provider's stock worth $28,000 after buying an additional 87 shares in the last quarter. Sentry Investment Management LLC raised its holdings in Align Technology by 73.1% in the 3rd quarter. Sentry Investment Management LLC now owns 187 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 79 shares in the last quarter. CYBER HORNET ETFs LLC bought a new stake in shares of Align Technology during the 2nd quarter valued at $36,000. MUFG Securities EMEA plc bought a new stake in shares of Align Technology during the 2nd quarter valued at $38,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Align Technology during the 3rd quarter worth $26,000. 88.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on ALGN. UBS Group raised their price target on Align Technology from $175.00 to $185.00 and gave the stock a "neutral" rating in a research report on Thursday, February 5th. Stifel Nicolaus increased their price objective on shares of Align Technology from $200.00 to $210.00 and gave the stock a "buy" rating in a research note on Thursday, February 5th. Morgan Stanley raised their target price on shares of Align Technology from $154.00 to $169.00 and gave the company an "equal weight" rating in a report on Thursday, February 5th. Wall Street Zen upgraded shares of Align Technology from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Finally, Evercore upped their price target on shares of Align Technology from $180.00 to $200.00 and gave the stock an "outperform" rating in a report on Thursday, February 5th. Six investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat, Align Technology currently has an average rating of "Hold" and a consensus target price of $198.08.

Align Technology Price Performance

Shares of NASDAQ ALGN opened at $169.43 on Wednesday. The company has a 50 day simple moving average of $175.21 and a 200 day simple moving average of $152.79. Align Technology, Inc. has a 1 year low of $122.00 and a 1 year high of $208.30. The firm has a market cap of $12.08 billion, a PE ratio of 29.93, a price-to-earnings-growth ratio of 1.91 and a beta of 1.79.

Align Technology (NASDAQ:ALGN - Get Free Report) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $3.29 earnings per share for the quarter, topping analysts' consensus estimates of $2.99 by $0.30. Align Technology had a net margin of 10.17% and a return on equity of 15.16%. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period in the previous year, the firm posted $2.44 EPS. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, research analysts anticipate that Align Technology, Inc. will post 7.98 earnings per share for the current fiscal year.

Insider Activity at Align Technology

In related news, EVP John Morici sold 7,969 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $189.31, for a total value of $1,508,611.39. Following the sale, the executive vice president owned 8,237 shares of the company's stock, valued at $1,559,346.47. The trade was a 49.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.66% of the company's stock.

About Align Technology

Align Technology, Inc NASDAQ: ALGN pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company's signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

Want to see what other hedge funds are holding ALGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Align Technology, Inc. (NASDAQ:ALGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.